eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Original paper

Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects

Aleksandra Lesiak
,
Anna Maćkowska
,
Igor A. Bednarski
,
Paweł Kolano
,
Irmina Olejniczak-Staruch
,
Anna Woźniacka
,
Joanna Sieniawska
,
Joanna Narbutt

Adv Dermatol Allergol 2019; XXXVI (4): 468-471
Online publish date: 2019/08/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Actinic keratosis is a common skin disease that occurs in response to prolonged exposure to ultraviolet radiation. This problem affects up to 60% of the population over 40 years of age. Actinic keratosis is considered to be a precancerous lesion leading to squamous cell carcinoma (SCC). The new therapeutic option for the treatment of actinic keratosis is ingenol mebutate gel (0.015%, 0.05%).

Aim
Retrospective evaluation of response and potential side effects of ingenol mebutate treatment in clinical practice.

Material and methods
Eight patients with actinic keratosis lesions on the face or scalp self-applied a 0.015% gel for 3 consecutive days on the 25 cm2 marked area. They were assessed at baseline and on day 4, 7, 14 and 57.

Results
All patients on day 57 presented a complete absence of AK lesions in the area of ingenol mebutate application. No adverse events were observed.

Conclusions
Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis.

keywords:

actinic keratosis, ingenol mebutate

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe